Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 2 of 15
Oct 10, 2026Aspen is using fresh clinical momentum around its Parkinson’s cell therapy sasineprocel to support a public-market move, while Bambusa is pitching a bispecific inflammation portfolio led by BBT001 in atopic dermatitis. The pair show that investors are still being asked to fund very different risk profiles, from a planned phase 3 launch to broad early clinical expansion.
Oct 9, 2026TRexBio began trading on Nasdaq under the ticker TRXB after selling 8.33 million shares at $14 each. The company said the proceeds, together with about $90.9 million in cash reported at the end of the second quarter of this year, should support operations into the second half of 2029.
Oct 8, 2026The agreement gives Ono access to Biohaven’s extracellular protein degrader platform at a point when BHV-1300 is already in phase 3 and two follow-on candidates remain behind it. For Biohaven, the transaction monetizes one of the R&D areas it chose to keep after cutting back broader ambitions in March.
Oct 8, 2026TCGX Asia Life Sciences Fund I will operate separately from, but in close synergy with, the firm's Western investment vehicles. The expansion pairs fresh capital with an on-the-ground buildout led by former ArriVent Biopharma chief business officer Dandan Dong.
Oct 7, 2026The round was co-led by Nextech Invest and Norwest, with returning investors Sanofi Ventures and Digitalis Ventures joined by Invus, BB Biotech, T1D Fund and BOLD Longevity Growth. The financing shows investors are still willing to fund platform-heavy biotech stories when they are tied to a near-term clinical catalyst and a defined disease focus.
Oct 7, 2026Caribou said the current financing environment for allogeneic CAR-T therapies made it impossible to secure the capital needed to keep advancing its programs. The company had reported $113.8 million in cash, cash equivalents and marketable securities as of June 30 and had previously said that runway could extend through the end of 2027.
Oct 6, 2026TRex Bio, Retension Pharmaceuticals and Lycia Therapeutics each moved a step closer to the Nasdaq with fresh SEC filings. The filings show a market still willing to fund development-stage biotech, but also one where companies are going public with highly specific use-of-proceeds plans tied to clinical execution.
Oct 6, 2026September trading in biotech was relatively muted at the index level, with the XBI down 3.5% for the month, but individual names still saw large swings tied to data and financing. Viking Therapeutics and Longeveron offered a clear split between a company able to raise fresh capital off positive obesity data and one forced into strategic review after its lead asset failed.
Oct 6, 2026The new agreement follows a July 2025 collaboration worth up to $856 million and gives Lilly another shot at a small-molecule drug class aimed at difficult-to-drug extracellular proteins. For Gate, the repeat deal is also a financing signal: a large pharma partner is increasing exposure before clinical proof of concept.
Oct 3, 2026Merck still faces the industry’s largest single-product replacement challenge, with Keytruda’s loss of exclusivity beginning at the end of 2028 and putting $33 billion in revenue at risk, according to BMO’s Sept. 9 report. But BMO argues Merck has already put multiple sizable assets in place, while Bristol Myers Squibb remains more dependent on riskier readouts from a smaller set of programs.
Oct 3, 2026The Boston-based immunotherapy startup was founded by researchers from Tufts University in 2014 to build therapies and diagnostics for ADAM8-positive cancers. Its lead preclinical program, AD100, aimed to inhibit ADAM8 and reprogram both lymphoid and myeloid cells, but the company had not reported a traditional seed or venture equity round.
Oct 2, 2026The new analysis from EMBARK and ENDEAVOR compared 25 treated patients with external controls and, according to Sarepta, showed clinically meaningful effects on ambulatory motor function, time to rise from the floor, and gait speed. For investors, the update matters because it arrives after deaths linked to the viral vector behind Elevidys and another Sarepta gene therapy, a temporary U.S. shipment suspension, and a narrowed label.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.